STOCK TITAN

Scynexis Inc - SCYX STOCK NEWS

Welcome to our dedicated news page for Scynexis (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scynexis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scynexis's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.23%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
Scynexis Inc

Nasdaq:SCYX

SCYX Rankings

SCYX Stock Data

53.02M
36.73M
2.88%
49.08%
2.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Jersey City

About SCYX

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.